Photometics has developed a uniquely effective therapy for Basal Cell Carcinoma, the most common form of skin cancer, affecting more than
1 million Americans annually.
Photometic's patented "selective photo-apoptosis" technology is based on decades of research into differential infrared absorption, determining and delivering the precise characteristics of light energy needed to kill cancer cells while leaving surrounding
Photometics’ vision is to advance cancer therapeutics through the
use of innovative light‐based technologies. A cancer therapy that disrupts cancer cells without drugs or chemicals, and without affecting healthy tissue, will be a true breakthrough improving a great many human lives.